Senseonics Holdings, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $484.3M
- Price
- $9.16
- % Change (Daily % change from the live per-ticker quote feed.)
- -8.03%
- Volume
- 635.9K
About
Senseonics Holdings, Inc. operates as a medical technology enterprise, specializing in the development and commercialization of continuous glucose monitoring (CGM) systems. These innovative solutions cater to individuals with diabetes across the United States, Europe, the Middle East, and Africa. The company's core product offerings, Eversense and Eversense XL, are advanced implantable CGM devices. They function by continuously tracking glucose levels through an under-the-skin sensor, a detachable and rechargeable smart transmitter, and an intuitive mobile application. This setup enables real-time diabetes monitoring and management for durations of up to half a year. Senseonics delivers its products and services to healthcare providers and patients alike via an extensive network of distributors and strategic fulfillment partners. Additionally, the firm maintains a collaborative agreement with the University Hospitals Accountable Care Organization. Founded in 1996, Senseonics Holdings, Inc. is headquartered in Germantown, Maryland.
Quick stats
Shares outstanding52.9M
Computed float50.1M
Float / shares94.8%
Key info
SectorHealthcare
IndustryMedical - Devices
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001616543
Websitehttps://www.senseonics.com
AI Summary
AI-generated1/22
standardbullishpartnership
Senseonics Announces Strategic Partnership with Beta Bionics to Integrate Eversense® 365 with the iLet® Bionic Pancreas
Beta Bionics is partnering with Senseonics to integrate the Eversense 365 implantable continuous glucose monitor with the iLet Bionic Pancreas automated insulin delivery system, pairing year-long glucose sensing with fully adaptive insulin dosing.
Development of the Eversense 365-iLet integration is expected to be completed during the fourth quarter of 2026, with commercial launch planned after testing, validation, and applicable regulatory requirements are satisfied.
For Beta Bionics, the deal broadens CGM choice within the iLet ecosystem and strengthens its position in the automated insulin delivery category; no financial terms of the partnership were disclosed.
Red flags
- No financial terms of the partnership disclosed
- Commercial launch contingent on completion of testing, validation, and regulatory requirements — execution and timeline risk into Q4 2026
- Forward-looking integration timelines are subject to coordination with a third-party partner, a cited risk factor by Senseonics